Examkin

Soru

Zorluk: OrtaBipolar and Related Disorders

A psychiatrist is evaluating a 32-year-old female patient who presents with a 4-week history of severe depressed mood, anhedonia, sleeping up to 14 hours per day, and profound fatigue. During the clinical interview, she reports feeling worthless but denies any active suicidal plans. A review of her medical records reveals a previous psychiatric hospitalization eight years ago for a 10-day episode of impulsivity, grandiosity, racing thoughts, and a significantly decreased need for sleep. Her medical history includes opioid use disorder, for which she is maintained on daily methadone therapy. She currently takes no other medications. Vital signs are normal. A baseline 12-lead electrocardiogram (ECG) is obtained and demonstrates a QTc interval of 515 ms. Based on this clinical presentation, which of the following is the most appropriate medication to initiate?

  1. A
    Citalopram
  2. B
    Quetiapine
  3. C
    Sertraline
  4. LurasidoneCevap
  5. E
    Venlafaxine

Cevap

Lurasidone is the most appropriate medication because it effectively treats bipolar depression without significantly prolonging the QTc interval.
This patient is experiencing an acute major depressive episode. Her history of a severe episode of elevated mood and grandiosity requiring hospitalization establishes a diagnosis of Bipolar I disorder. First-line pharmacotherapy for acute bipolar depression includes lurasidone, quetiapine, cariprazine, or lithium. However, this patient is taking methadone and has a significantly prolonged baseline QTc interval (515 ms; normal < 470 ms in women). Lurasidone is highly effective for bipolar depression and has a minimal risk of QTc prolongation, making it the safest and most appropriate choice.

Adım Adım Çözüm

1
Identify the patient's primary psychiatric diagnosis based on her history and current presentation.
The patient has a history of a manic episode (hospitalization for elevated mood, decreased sleep, grandiosity) and is currently experiencing a major depressive episode. This establishes a diagnosis of Bipolar I disorder.
Distinguishing bipolar depression from unipolar major depressive disorder is critical, as treatment pathways differ significantly.
2
Evaluate the patient's current medication regimen and baseline diagnostics to identify any contraindications for pharmacotherapy.
The patient is on methadone (a known QTc-prolonging agent) and has a significantly prolonged baseline QTc interval of 515 ms on her ECG.
Many psychiatric medications can further prolong the QTc interval, leading to an unacceptable risk of fatal arrhythmias like Torsades de Pointes.
3
Select the most appropriate first-line pharmacotherapy for bipolar depression that minimizes the risk of QTc prolongation and avoids a manic switch.
Lurasidone is selected over quetiapine (due to QTc risk) and over SSRIs/SNRIs (due to manic switch risk).
Lurasidone is FDA-approved for bipolar depression and is among the second-generation antipsychotics with the lowest risk of QTc prolongation.

Anahtar Kavram

Pharmacological management of acute bipolar depression in patients with baseline QTc prolongation.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Bipolar and Related Disorders

Bu konudan daha fazla soru